Please login to the form below

Not currently logged in
Email:
Password:

Takeda will acquire Nycomed, reports say

Takeda Pharmaceutical Company has agreed to buy Swiss drugmaker Nycomed in a deal worth around 1trn yen ($12bn), according to a report in Japanese newspaper, Nikkei

Takeda Pharmaceutical Company has agreed to buy Swiss drugmaker Nycomed in a deal worth around 1trn yen ($12bn), according to a report in Japanese newspaper, Nikkei.

The report follows denials by Takeda, the largest pharma company in Japan, earlier this month: "Takeda has not agreed to any such agreement as suggested by certain newspaper publications… Takeda is constantly seeking and evaluating opportunities to increase shareholder value and enhance our business through strategic investment, however, there is nothing that needs to be announced at this point."

Initial media reports had alleged that the deal was in its final stages, while another said that Takeda is talking to banks about financing the deal.

Rumours of the deal came just days after Nycomed entered into a co-branding agreement with Almirall to commercialise roflumilast in Spain. Romflumilast is a once-daily tablet for patients with COPD. It is an orally administered phosphodiesterase 4 (PED4) enzyme inhibitor and the first oral anti-inflammatory treatment for COPD.

Related stories
Takeda denies Nycomed takeover talks
Almirall/Nycomed COPD co-branding deal

18th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics